Back to Search
Start Over
Disease burden of respiratory syncytial virus infection in the pediatric population in Japan.
- Source :
-
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2022 Feb; Vol. 28 (2), pp. 146-157. Date of Electronic Publication: 2021 Dec 21. - Publication Year :
- 2022
-
Abstract
- Introduction: Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory tract infections in children aged <5 years and is associated with long-term respiratory morbidities such as recurrent wheezing and asthma, decreased lung function, and allergic sensitization. The objective of this review was to evaluate the epidemiology and burden of RSV infection in the pediatric population in Japan.<br />Methods: Studies indexed in PubMed and ICHUSHI databases during January 2010-December 2020 were manually reviewed. Data on proportion of RSV infections, seasonality, length of stay (LoS), mortality, medical expenses, and palivizumab use were extracted from the selected articles.<br />Results: Ninety-three articles were included (PubMed, 64; ICHUSHI, 29). The proportion of patients/samples with an RSV infection was 5.5%-66.7%, and 6.0%-29.9% in the inpatient and outpatient departments, respectively. RSV infections generally occurred during autumn/winter; however, recently the peak has shifted to summer. The LoS was variable and depended on factors such as age, infection severity, wheezing, and RSV subgroups. Mortality rates varied from <1% to 19% depending on the infection severity. The average daily hospitalization and intensive care unit cost was JPY 34,548 while intensive care unit incurred an additional cost of JPY 541,293. Palivizumab was indicated for high-risk infants and 0%-3% of patients required hospitalization despite palivizumab use.<br />Conclusions: RSV imposes a significant burden on the Japanese healthcare system, suggesting a need to create awareness among caregivers of children, pregnant women and healthcare professionals to ensure early recognition of infection and adequate treatment or prophylaxis.<br /> (Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Antibodies, Monoclonal, Humanized therapeutic use
Antiviral Agents therapeutic use
Child
Cost of Illness
Female
Hospitalization
Humans
Infant
Japan epidemiology
Palivizumab therapeutic use
Pregnancy
Respiratory Syncytial Virus Infections drug therapy
Respiratory Syncytial Virus Infections epidemiology
Respiratory Syncytial Virus, Human
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7780
- Volume :
- 28
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 34952776
- Full Text :
- https://doi.org/10.1016/j.jiac.2021.11.007